Age-adjusted charlson comorbidity index and 30-day morbidity in pelvic surgeries

Abstract

Introduction:Charlson comorbidity index (CCI) is a validated tool enabling clinicians for prediction of adverse events posttherapy. In this study, we planned to estimate the predictive value of age-adjusted CCI (ACCI) in assessing the perioperative complication in oncological patients undergoing major pelvic surgeries.Methods:This was a single arm, prospective, observational study, in which adult patients with pelvic malignancies undergoing pelvic surgeries were selected. The relationship between the ACCI and Grade 3–5 adverse events were tested using Fisher's test.Results:The rate of Grade 3–5 adverse event rate was 16.7% (11 patients, n = 66). Among the whole cohort, 11 patients (16.7%) had high score on ACCI. The rate of Grade 3–5 adverse events was higher in the cohort of patients with high ACCI score (45.5% vs. 10.9%, P = 0.014). The sensitivity, specificity and negative and positive predictive values were 45.5%, 89.1%, 89.1%, and 45.5%, respectively.Conclusion:ACCI can predict for postsurgical adverse events. It has a high negative predictive value for nonoccurrence of adverse events.

Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly

“…The survey included questions about basic demographic information, body and height measures, smoking status, current medications, previous COVID-19 diagnosis, and history of rheumatic diseases, inflammatory disease, malignancy (solid organ or hematologic), transplantation, or immune-suppressive use. Comorbid diseases were identified according to Charlson index list [ 17 ]. Those who had contracted COVID-19 verified with positive PCR test or those who were considered symptomatic for COVID-19 infection but had negative PCR test were not included in the study.…”

“…Spearmen correlation test was used to investigate association between antibody titer and age. We calculated age adjusted Charlson comorbidity index as reported [ 17 ]. We analyzed antibody titers categorically.…”

Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort

“…Selected patients who presented fast radiological progression, increased oxygen needs, and progressive increase of CRP, D-dimer, ferritin, AST, ALT levels and marked lymphopenia were labeled as candidates for bad prognosis and suitable to receive iv TCZ to prevent severe CRS. An expert committee evaluated the suitability of iv TCZ considering risk/benefit ratio and prescribed the therapy short early in the course of clinical onset of CRS, according to more than one of the following criteria: 1) Age-adjusted Charlson Comorbidity Index scores<4 [ 17 ], 2) Interstitial pneumonia with severe respiratory failure (score = 2 on the COVID respiratory severity scale), 3) rapid respiratory worsening requiring non-invasive or invasive ventilation (score ≥ 3 on the COVID respiratory severity scale). The presence of severe systemic inflammatory response criteria was confirmed by: high levels of D-dimer (>1500 ng/ mL) or progressively increasing D-dimer or alternatively high levels of IL-6 (>40 pg/mL).…”

Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2

“…Age-adjusted Charlson Comorbidity Index scores <4, [ 12 ]…”